Neurology drugs
55 results
Abilify asimtufii (aripiprazole)
(Aripiprazole)Otsuka America Pharmaceutical, Inc
Usage: ABILIFY ASIMTUFII is indicated for the treatment of schizophrenia in adults and for the maintenance monotherapy treatment of bipolar I disorder in adults.
Abilify maintena (aripiprazole)
(aripiprazole)Otsuka America Pharmaceutical, Inc.
Usage: ABILIFY MAINTENA (aripiprazole) is indicated for the treatment of schizophrenia in adults and for the maintenance monotherapy treatment of bipolar I disorder in adults.
Aldurazyme (laronidase)
(laronidase)Genzyme Corporation
Usage: ALDURAZYME® is indicated for treating adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I), and for those with moderate to severe symptoms of the Scheie form. Its safety and effectiveness in mildly affected Scheie patients and CNS effects are not established.
Amvuttra (vutrisiran)
(VUTRISIRAN)Alnylam Pharmaceuticals, Inc.
Usage: AMVUTTRA is indicated for treating the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) and the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults, focusing on reducing cardiovascular mortality, hospitalizations, and urgent heart failure visits.
Apokyn (apomorphine hydrochloride)
(APOMORPHINE HYDROCHLORIDE)MDD US Operations, LLC
Usage: APOKYN (apomorphine hydrochloride injection) is indicated for the acute, intermittent treatment of hypomobility during "off" episodes in patients with advanced Parkinson's disease, including both end-of-dose wearing off and unpredictable "on/off" episodes. It may be used alongside other medications.
Austedo (deutetrabenazine)
(Deutetrabenazine)Teva Neuroscience, Inc.
Usage: AUSTEDO XR and AUSTEDO are indicated for the treatment of chorea associated with Huntington’s disease and tardive dyskinesia in adults.
Cerdelga (eliglustat)
(eliglustat)Genzyme Corporation
Usage: CERDELGA is indicated for the long-term treatment of adults with Gaucher disease type 1 (GD1) who are CYP2D6 extensive, intermediate, or poor metabolizers. It is not recommended for ultra-rapid metabolizers or patients with indeterminate CYP2D6 genotypes due to potential inadequate therapeutic effect.
Cerezyme (imiglucerase)
(IMIGLUCERASE)Genzyme Corporation
Usage: Cerezyme is indicated for the treatment of adults and pediatric patients aged 2 years and older with Type 1 Gaucher disease, addressing conditions such as anemia, thrombocytopenia, bone disease, and hepatomegaly or splenomegaly.
Cobenfy (xanomeline and trospium chloride)
(xanomeline and trospium chloride)E.R. Squibb & Sons, L.L.C.
Usage: COBENFY is indicated for the treatment of schizophrenia in adults.
Daybue (trofinetide)
(trofinetide)Acadia Pharmaceuticals Inc.
Usage: DAYBUE is indicated for the treatment of Rett syndrome in adults and pediatric patients aged 2 years and older.